Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $1 |
| Enterprise Value | $0 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 12.1% | 11.8% | -7.2% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 100% | 29.3% | -23.5% | -250.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -59.7% | -89.9% | -148.2% | -420.9% |
| Net Income | -$0 | -$0 | $1 | -$0 |
| % Margin | -87.6% | -96.1% | 1,698.5% | -360.6% |
| EPS Diluted | -1.15 | -1 | -1.26 | -2.87 |
| % Growth | -15% | 20.6% | 56.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |